Patents by Inventor Charles Alan Reavill

Charles Alan Reavill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Transgenic mouse EDG2 knockout model
    Patent number: 7038105
    Abstract: The present invention provides a transgenic non-human animal and method for using the same in evaluating a therapeutic agent for use in the treatment of Schizophrenia. More specifically, the invention is directed to a transgenic non-human animal which is incapable of expressing functional EDG2 protein. A theraupeutic agent is administered to the transgenic non-human animal incapable of expressing functional EDG2 protein and the effect of the agent on the animal is evaluated.
    Type: Grant
    Filed: August 22, 2002
    Date of Patent: May 2, 2006
    Assignee: Smithkline Beecham Corporation
    Inventors: Peter Ronald Maycox, Charles Alan Reavill
  • Use of 5HT-6 antagonists
    Patent number: 6627661
    Abstract: Methods for treating ADHD, comprising administering 5-HT6 antagonists to subjects having ADHD, are disclosed.
    Type: Grant
    Filed: March 13, 2002
    Date of Patent: September 30, 2003
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Charles Alan Reavill, Carol Routledge
  • Model
    Publication number: 20030056236
    Abstract: The present invention provides a transgenic non-human animal and method for using the same in evaluating a therapeutic agent for use in the treatment of Schizophrenia. More specifically, the invention is directed to a transgenic non-human animal which is incapable of expressing functional EDG2 protein. A theraupeutic agent is administered to the transgenic non-human animal incapable of expressing functional EDG2 protein and the effect of the agent on the animal is evaluated.
    Type: Application
    Filed: August 22, 2002
    Publication date: March 20, 2003
    Inventors: Peter Ronald Maycox, Charles Alan Reavill
  • Use of 5HT-6 antagonists
    Publication number: 20020094979
    Abstract: The invention relates to the use of 5-HT6 receptor antagonists containing arylsulfamide or arylaminosulfonyl groups in the manufacture of a medicament for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
    Type: Application
    Filed: March 13, 2002
    Publication date: July 18, 2002
    Inventors: Charles Alan Reavill, Carol Routledge
  • Use of 5HT6 antagonists
    Patent number: 6380199
    Abstract: A method of treating ADHD comprising administering a 5-HT6 receptor antagonist according to formula (A) hereinbelow: wherein: P is phenyl, naphthyl, a bicyclic heterocyclic ring or is a 5 to 7-membered heterocyclic ring each containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulphur; A is a single bond, a C1-6alkylene or a C1-6alkenylene group; R1 is halogen, C1-6alkyl optionally substituted by one or more halogen atoms, C3-6cycloalkyl, C1-6alkoxy, OCF3, hydroxy, hydroxyC1-6alkyl, hydroxyC1-6alkoxy, C1-6alkoxyC1-6alkoxy, C1-6alkanoyl, nitro, amino, C1-6alkylamino or diC1-6alkylamino, cyano or R1 is phenyl, naphthyl, a bicyclic heterocyclic ring or is a 5 to 7-membered heterocyclic ring each containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulphur; n is 0, 1, 2, 3, 4, 5 or 6, R2 is hydrogen, C1-6 alkyl or aryl C1-6 alkyl; R3 is a group R5 or together with R5 forms a group (CH2)2O or (CH2)3O or R3 is linked to R2 to form a group (CH2)2 or (CH2)3; R4 is &mdash
    Type: Grant
    Filed: April 17, 2001
    Date of Patent: April 30, 2002
    Assignee: SmithKline Beechan p.l.c.
    Inventors: Charles Alan Reavill, Carol Routledge